𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn’s disease: a retrospective data analysis in Germany

✍ Scribed by Thomas Witthöft; Diether Ludwig

Publisher
Springer
Year
2004
Tongue
English
Weight
167 KB
Volume
20
Category
Article
ISSN
0179-1958

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of concurrent na
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
✍ Bruce E. Sands; Richard Kozarek; Jack Spainhour; Charles F. Barish; Scott Becker 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 2 views

## Background: Natalizumab, a humanized monoclonal igg(4) antibody to alpha4 integrin, was investigated as a treatment of active crohn's disease (cd). the safety of natalizumab given in combination with infliximab has not previously been studied. ## Methods: Seventy-nine adult patients with activ

Effects of infliximab therapy on abdomin
Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease
✍ Erika Parmentier-Decrucq; Alain Duhamel; Olivier Ernst; Catherine Fermont; Alexa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Background: Tumor necrosis factor is an adipocytokine possessing a well-established lipolytic effect. in crohn's disease (cd) patients, infliximab therapy may thus result in visceral fat accumulation, which is associated with an increased risk of metabolic syndrome. ## Methods: A total of 132